BMC Infectious Diseases最新文献

{"title":"Use of interferon-gamma release assay (IGRA) and CXCL-10/IP-10 for latent tuberculosis infection (LTBI) screening in chronic kidney disease and hemodialysis patients.","authors":"Juliana Cristina Borges da Silva, Nathália Barcellos Vieira, Marcelo Ribeiro-Alves, Roberto Stefan de Almeida Ribeiro, Carla Cavalheiro da Silva Lemos, Renata Mendes, Conrado Lysandro Rodrigues Gomes, Ana Paula Santos, José Hermógenes Suassuna, Rachel Bregman, Luciana Silva Rodrigues","doi":"10.1186/s12879-025-11620-z","DOIUrl":"10.1186/s12879-025-11620-z","url":null,"abstract":"","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1224"},"PeriodicalIF":3.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145211508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Machine learning model for differentiating Pneumocystis jirovecii pneumonia from colonization and analyzing mortality risk in non-HIV patients using BALF metagenomic sequencing.","authors":"Yuhui Chen, Yiwei Bai, Meng Li, Xinai Gan, Yutong Wang, Yongzhao Zhou, Ting Niu","doi":"10.1186/s12879-025-11576-0","DOIUrl":"10.1186/s12879-025-11576-0","url":null,"abstract":"","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1222"},"PeriodicalIF":3.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12490100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145205047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of the BIOFIRE^® FILMARRAY^® Pneumonia plus Panel to characterize the etiology of lower respiratory tract infections among hospitalized patients in Southern Province, Sri Lanka.","authors":"Zachary A Weishampel, Ajith Nagahawatte, Gaya Wijayaratne, Subodha S Wickramasinghe, Bradly Nicholson, Jack Anderson, Sky Vanderburg, Chathuranga Lakmal Fonseka, Madureka Premamali, Robert J Rolfe, U H B Y Dilshan, Ruvini Kurukulasooriya, D L B Piyasiri, Truls Østbye, Christopher W Woods, Lana Abusalem, Armstrong Obale, L Gayani Tillekeratne, Champica K Bodinayake","doi":"10.1186/s12879-025-11562-6","DOIUrl":"10.1186/s12879-025-11562-6","url":null,"abstract":"<p><strong>Background: </strong>Lower respiratory tract infections (LRTIs) account for a heavy burden of illness in low- and middle-income country settings, but the etiology of these infections is often unknown. In this study, we applied the BIOFIRE^® FILMARRAY^® Pneumonia plus Panel, a multiplex polymerase chain reaction assay with bacterial, viral, and antibacterial resistance gene targets, on sputum samples to evaluate the etiology of community-acquired LRTI among hospitalized patients in southern Sri Lanka.</p><p><strong>Methods: </strong>We enrolled children and adults hospitalized with LRTIs at a public tertiary care hospital in southern Sri Lanka from 2019 to 2021. Demographic and clinical data were collected, and a sputum sample for each patient was tested using the Pneumonia plus Panel. Assay results were compared with sputum culture results. Fisher's exact test was applied to identify association between the presence of viruses, bacteria, or antimicrobial resistant genes and the findings of the chest radiographs during hospitalization as well as associations between the genomic concentration identified through the panel and the bacteria known to cause typical pneumonia infection included in the panel.</p><p><strong>Results: </strong>In 267 patients tested, the most detected bacteria by the Pneumonia plus Panel were the Klebsiella pneumoniae group (41.9%), Staphylococcus aureus (34.5%), and the Acinetobacter calcoaceticus-baumannii complex (32.6%). The most detected viruses were the human rhinovirus/enterovirus (19.5%) and influenza A (10.9%). In total, 211 patients (79.0%) had at least one gram-negative bacterium and 139 patients (52.1%) had at least one gram-positive bacteria. As for Antimicrobial Resistance, 96 patients (40.0%) had at least one carbapenem resistant gene, 56 patients (21.0%) had an extended spectrum beta-lactamase related gene, and 42 patients (15.7%) had a methicillin resistant gene. Only 15 patients (5.6%) were identified to have Pneumonia plus Panel results matching with sputum culture results.</p><p><strong>Conclusions: </strong>Our findings suggest that patients with LRTI in Southern Province, Sri Lanka have a high prevalence of gram-negative bacteria and antibacterial resistance in their sputum samples. However, it remains difficult to differentiate isolates that are colonizers not leading to disease versus the true cause of infection via the use of the BIOFIRE^® FILMARRAY^® Pneumonia plus Panel on sputum samples.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1178"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482574/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of direct-acting antiviral treatment outcomes in patients with chronic hepatitis C infected with various HCV genotypes: Insights from a real-world cohort in West Bengal, India.","authors":"Supradip Dutta, Shreyasi Nath, Raina Das, Sagnik Bakshi, Moumita Majumdar, Anwesha Ghosh, Upasana Baskey, Prosanto Kumar Chowdhury, Provash Chandra Sadhukhan","doi":"10.1186/s12879-025-11565-3","DOIUrl":"10.1186/s12879-025-11565-3","url":null,"abstract":"<p><strong>Background & objectives: </strong>Genomic diversity of Hepatitis C Virus (HCV), accessibility and long-term influence of Direct Acting Antiviral (DAA) treatment remain underexplored among HCV-infected chronic liver disease (CLD) patients in the real world. This retrospective study addressed the inadequacy of assessing the effectiveness of DAA and identify genotype-specific variations in treatment response in the context of HCV epidemiology. Additionally, real-world treatment challenges encountered during the COVID-19 pandemic and the transitional phase of implementing the National Viral Hepatitis Control Program (NVHCP) guidelines have also been addressed.</p><p><strong>Methods: </strong>This retrospective study included 254 CLD patients from November 2017 and February 2020 to assess the effectiveness of DAA and long-term treatment outcomes among CLD patients.</p><p><strong>Results: </strong>HCV viremia was observed in 58.26% (n = 148) patients. Patients aged 52-59 years with a history of blood transfusions exhibited a higher prevalence of active HCV infection. Two major genotypes (GT) - GT1 and GT3, and seven subtypes with few new subtypes were identified. SVR₂₄ was achieved in 89.6% of patients receiving sofosbuvir (SOF) + daclatasvir (DCV) or SOF/ledipasvir (LDV) drug regimens. For individuals who failed to reach SVR₂₄ (n = 13), a modified regimen (SOF + Velpatasvir (VEL) + ribavirin (Riba) for 6 months) was given and the success rate was 92.31%. GT-1a and GT-1b showed better treatment response, whereas GT-3b had a lower treatment response. Among 77 SVR₂₄ achieved patients, 57.14% were cirrhotic and 42.86% were non-cirrhotic at the start of the therapy.</p><p><strong>Interpretation & conclusion: </strong>This study highlights genotype-specific variations in treatment response, with GT-3b exhibiting lower treatment response which highlights the need to decipher the reasons behind treatment failure for future therapeutic management.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1180"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cefixime-clavulanic acid in ESBL-producing E. coli lower urinary tract infections: a 13-patient case series.","authors":"Sinan Mermer, Deniz Akyol, Mehmet Buğra Özkara, Sabire Şöhret Aydemir, Oğuz Reşat Sipahi","doi":"10.1186/s12879-025-11690-z","DOIUrl":"10.1186/s12879-025-11690-z","url":null,"abstract":"<p><strong>Background: </strong>Urinary tract infections (UTIs) represent a substantial proportion of community-acquired infections. The increasing prevalence of Escherichia coli strains that produce extended spectrum beta-lactamases (ESBL) poses a significant obstacle to effective infection treatment. Although carbapenems remain highly effective against ESBL-producing isolates, their use in lower UTIs is limited by the need for intravenous or intramuscular administration, hospitalization, high cost, and the risk of collateral damage due to their broad-spectrum activity. Therefore, there is a growing need for effective oral alternatives.</p><p><strong>Methods: </strong>This retrospective study evaluated the clinical and microbiological outcomes of 13 patients diagnosed with lower UTIs caused by ESBL-producing E. coli (ESBL-PE), treated with oral cefixime-clavulanic acid (400/125 mg every 12 hours for 14 days). Follow-up urine cultures were obtained on days 3-5 and/or at the end of treatment (days 11-14).</p><p><strong>Results: </strong>On days 3-5 of treatment, microbiological and clinical success rates were 53.8% (7/13) and 61.5% (8/13) respectively. At the end of the treatment, urine culture results could be evaluated in 10 cases, microbiological success was 80% (8/10). Clinical success was 84.6% (11/13). Re-infection and relapse rates on day 30 post-treatment were 7.7% (1/13) and 30.8% (4/13), respectively.</p><p><strong>Conclusions: </strong>Cefixime-clavulanic acid may be considered an alternative to older antibiotics such as fosfomycin and nitrofurantoin in the treatment of uncomplicated urinary tract infections, and may also contribute to the prevention of carbapenem resistance development. However, these findings should be interpreted with caution due to important limitations, including the small sample size, retrospective design, absence of standardized minimum inhibitor concentration (MIC) testing, and lack of a control group. Larger prospective studies are needed to confirm these results.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1218"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Submandibular gland abscess and bacteremia caused by Dialister micraerophilus in a patient with Sjögren's syndrome: a case report.","authors":"Tinghua Ye, Bin Lu, Sipei Wang, Lulu Jin, Xinling Pan","doi":"10.1186/s12879-025-11563-5","DOIUrl":"10.1186/s12879-025-11563-5","url":null,"abstract":"<p><strong>Background: </strong>Infection caused by Dialister micraerophilus (D. micraerophilus), a slow-growing, anaerobic or microaerophilic, small gram-negative coccobacillus, has been rarely reported, and its clinical characteristics remain insufficiently defined.</p><p><strong>Case presentation: </strong>A 59-year-old woman presented with a submandibular gland abscess and bacteremia caused by D. micraerophilus. The underlying etiology of this infection was salivary gland dysfunction associated with Sjögren's syndrome (SS), which led to submandibular gland abscess formation and subsequent hematogenous dissemination, resulting in bacteremia. Identification of D. micraerophilus was achieved using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 16 S rRNA gene sequencing. The patient achieved complete clinical recovery following intravenous piperacillin-tazobactam (4.5 g every 8 h) during hospitalization, followed by a 10-day course of oral amoxicillin-clavulanic (0.375 g every 8 h) after discharge.</p><p><strong>Conclusions: </strong>This case describes bacteremia with D. micraerophilus in a patient with SS complicated by a submandibular gland abscess. Clinical management of such patients should emphasize oral hygiene education and rigorous aseptic techniques during dental procedures to reduce the risk of infection.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1185"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The epidemiology of hepatitis b virus infection in Uganda after two decades of vaccination: a meta-analysis and meta-regression.","authors":"Hussein Mukasa Kafeero, Hakim Sendagire, Dorothy Ndagire, Abdul Walusansa, Ali Kudamba, Fahad Muwanda, Mariam Namusoke, Ponsiano Ocama","doi":"10.1186/s12879-025-11582-2","DOIUrl":"10.1186/s12879-025-11582-2","url":null,"abstract":"","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1174"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between mental health symptoms and autoimmunity in patients with long COVID.","authors":"Hernan F Guillen-Burgos, Mauricio Sarmiento, Juan F Gálvez-Flórez, Catalina Rojas, Yaneth Beatriz Lora, Ivan David Lozada-Martinez, María C Diazgranados-Garcia, Gibacus, Manuel Rojas, Juan Carlos Salazar-Uribe, Juan-Manuel Anaya","doi":"10.1186/s12879-025-11536-8","DOIUrl":"10.1186/s12879-025-11536-8","url":null,"abstract":"<p><strong>Background: </strong>Neuropsychiatric symptoms are common features in long COVID. The pathogenesis of neuropsychiatric manifestations in both acute COVID-19 and long COVID remains unclear. This study aimed to examine mental health symptoms-depressive, anxiety, and insomnia symptoms-in COVID-19 survivors with long COVID, and to explore their potential association with autoimmune activity.</p><p><strong>Methods: </strong>We conducted an observational, cross-sectional study of 228 adults recruited from a long COVID program in Cartagena, Colombia. Participants underwent clinician-administered interviews and completed validated psychometric scales to assess depressive (PHQ-9), anxiety (GAD-7), and insomnia (ISI) symptoms. Sociodemographic, clinical, and biological data were collected. The autoantibody panel included antinuclear antibodies (ANA), anti-SSA/Ro, anti-SSB/La, anti-RNP, anti-Smith (Sm), rheumatoid factor (RF), anti-thyroglobulin (Tg), and anti-thyroid peroxidase (TPO), measured via ELISA and immunofluorescence. Robust logistic regression models were used to evaluate associations between long COVID, autoantibody positivity, and mental health symptoms, adjusting for age, sex, and relevant covariates.</p><p><strong>Results: </strong>57% of participants with a history of COVID-19 acute infection reported long COVID. In participants with long COVID, we reported high proportions of depressive (21.2%), anxiety (31.2%), and insomnia (28.7%) symptoms. Moreover, an association of all three mental health symptoms with autoantibody positivity (particularly antinuclear antibodies [ANA] isolated or co-occurring with anti-TPO antibodies) was observed in individuals with long COVID. Our findings suggest a potential association between psychopathological symptoms, autoantibody positivity, and distinct clinical profiles of long COVID, warranting further longitudinal investigation.</p><p><strong>Conclusions: </strong>Mental health symptoms (MHS) should be considered one of the main targets involved in translational research in long COVID. There is an urgent need for consultation-liaison physicians to work closely with immunologists, rheumatologists, and pain medicine physicians in clinical settings as well as in research. This will contribute to a better understanding of the impact of MHS during illness in long COVID variants.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1220"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482054/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermittent loss of anti-HBc antibodies in people with multiple sclerosis undergoing disease-modifying therapies.","authors":"Patrizia Pasculli, Yann Collins Fosso Ngangue, Maria Antonella Zingaropoli, Federica Dominelli, Federica Ciccone, Michele Antonacci, Gina Ferrazzano, Roberta Campagna, Ombretta Turriziani, Guido Antonelli, Claudio Maria Mastroianni, Antonella Conte, Maria Rosa Ciardi","doi":"10.1186/s12879-025-11586-y","DOIUrl":"10.1186/s12879-025-11586-y","url":null,"abstract":"<p><strong>Background: </strong>Disease-modifying therapies (DMTs) are widely used in the treatment of multiple sclerosis (MS). A mounting body of evidence suggests that the risk of hepatitis B virus (HBV) reactivation is primary associated with anti-CD20 therapies. HBV infection leads to the development of anti-HBc antibodies, which typically persist for life. However, the existing literature also highlights the intermittent loss of anti-HBc antibodies in certain immunocompromised individuals. The present study aims to gather real-world evidence on the risk of infection in people with MS (pwMS) prior to the initiation or modification of DMTs, with a particular focus on HBV reactivation and the dynamics of anti-HBc antibody levels in this population.</p><p><strong>Materials and methods: </strong>At the Neuroinfectious Unit, pwMS were longitudinally evaluated for infectious risk before starting, switching, or during DMTs, with a particular focus on the course of anti-HBc antibodies over time during anti-CD20 treatment.</p><p><strong>Results: </strong>A seven-year retrospective and observational study was conducted, with 318 pwMS enrolled (183 females and 135 males, with a median age [interquartile range, IQR] of 51 [41-60] years). Among 110 anti-CD20 treated pwMS, 15 were anti-HBc positive, with negative or positive HBsAg, and positive or negative anti-HBs antibodies. In 2/15 of pwMS HBsAg was positive, detectable HBV-DNA was found in blood and start specific antiviral therapy before DMT. During anti-CD20 therapy, four out of the fifteen pwMS showed a transient loss of anti-HBc following the start of anti-CD20 treatment. Moreover, during this seven-year retrospective and observational study, two pwMS showed HBV reactivation.</p><p><strong>Conclusions: </strong>The findings of this observational cohort study demonstrated the intermittent loss of anti-HBc antibodies in pwMS during anti-CD20 therapy. It is imperative that infectious disease screening is performed on pwMS before starting DMTs to define the serological profile and to mitigate the risk of infection, allowing for the avoidance of discontinuing MS therapy and guaranteeing a higher degree of safety.</p><p><strong>Trial registration: </strong>Clinical trial number: not applicable.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1179"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12482589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of toxoplasmosis by serology and nested-PCR in kidney transplant recipients and patients on hemodialysis from Sri Lanka.","authors":"Gpc Weerasooriya, A Manamperi, Bmha Banneheke","doi":"10.1186/s12879-025-11353-z","DOIUrl":"10.1186/s12879-025-11353-z","url":null,"abstract":"<p><p>Toxoplasmosis, the parasitic disease caused by Toxoplasma gondii (T.gondii) affects approximately one-third of the global population. In immunocompromised patients who had been previously infected with T.gondii, the parasite can reactivate to cause infection. This study aimed to determine the seroprevalence of T.gondii among kidney transplant recipients (KTR) and hemodialysis patients (HD) by enzyme-linked immunosorbent assay (ELISA) and to detect T.gondii Deoxyribonucleic Acid (DNA) by nested-Polymerase Chain Reaction (nPCR). Of the 342 patients (114 KTR and 228 HD), 64 (18.7%) and 123 (36%) showed evidence of acute and past infection, respectively, by ELISA, while two (0.6%) had indeterminate results and 153 (44.7%) were negative. In nPCR, there were 28 (8.2%) positives, of which 6.1% only IgG positives, 1.2% only IgM positives, 0.6% both IgM and IgG positives, and 0.3% were indeterminates. The importance of using a combination of serology and molecular methods to determine toxoplasmosis status before commencing treatment in patients awaiting KTR and undergoing HD is indicated by these results. This is the first study that determined toxoplasmosis seroprevalence and targeted the B1 gene using nPCR method to detect toxoplasmosis among KTR and HD patients in Sri Lanka.</p>","PeriodicalId":8981,"journal":{"name":"BMC Infectious Diseases","volume":"25 1","pages":"1207"},"PeriodicalIF":3.0,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12481815/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}